Maccura Biotech shareholder stakes rise after restricted stock buyback

Maccura Biotechnology announced that its controlling shareholders, actual controllers, and their concert parties experienced a passive increase in their combined shareholding percentage from 23.98% to 24.13%. This change resulted from the company's buyback and cancellation of 3,844,966 restricted shares from its 2024 Restricted Stock Incentive Plan, reducing the total share capital from 612,469,590 shares to 608,624,624 shares. The transaction, completed on August 27, 2025, did not involve any change in the number of shares held by the shareholders, nor did it involve any share acquisition or disposal.

The buyback and cancellation, approved by the company's general meeting on June 27, 2025, involved a total of 24,941,489.25 yuan from the company's own funds. The share capital adjustment, audited by Lixin Certified Public Accountants, was completed on August 15, 2025. This passive increase in shareholding percentage does not affect the company's control or its governance structure and continuous operations, ensuring it remains eligible for listing.